These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

639 related articles for article (PubMed ID: 25951996)

  • 1. SILA-421 activity in vitro against rifampicin-susceptible and rifampicin-resistant Mycobacterium tuberculosis, and in vivo in a murine tuberculosis model.
    de Knegt GJ; Bakker-Woudenberg IA; van Soolingen D; Aarnoutse R; Boeree MJ; de Steenwinkel JE
    Int J Antimicrob Agents; 2015 Jul; 46(1):66-72. PubMed ID: 25951996
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Enhancement of in vitro activity of tuberculosis drugs by addition of thioridazine is not reflected by improved in vivo therapeutic efficacy.
    de Knegt GJ; ten Kate MT; van Soolingen D; Aarnoutse R; Boeree MJ; Bakker-Woudenberg IA; de Steenwinkel JE
    Tuberculosis (Edinb); 2014 Dec; 94(6):701-7. PubMed ID: 25621361
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Activity of rifampicin and linezolid combination in Mycobacterium tuberculosis.
    Maltempe FG; Caleffi-Ferracioli KR; do Amaral RCR; de Oliveira Demitto F; Siqueira VLD; de Lima Scodro RB; Hirata MH; Pavan FR; Cardoso RF
    Tuberculosis (Edinb); 2017 May; 104():24-29. PubMed ID: 28454646
    [TBL] [Abstract][Full Text] [Related]  

  • 4. SILA 421, an inhibitor of efflux pumps of cancer cells, enhances the killing of intracellular extensively drug-resistant tuberculosis (XDR-TB).
    Martins M; Viveiros M; Ramos J; Couto I; Molnar J; Boeree M; Amaral L
    Int J Antimicrob Agents; 2009 May; 33(5):479-82. PubMed ID: 19155160
    [TBL] [Abstract][Full Text] [Related]  

  • 5. In vitro and in vivo activity of biapenem against drug-susceptible and rifampicin-resistant Mycobacterium tuberculosis.
    Kaushik A; Ammerman NC; Tasneen R; Story-Roller E; Dooley KE; Dorman SE; Nuermberger EL; Lamichhane G
    J Antimicrob Chemother; 2017 Aug; 72(8):2320-2325. PubMed ID: 28575382
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Activity of ketoconazole against Mycobacterium tuberculosis in vitro and in the mouse model.
    Byrne ST; Denkin SM; Gu P; Nuermberger E; Zhang Y
    J Med Microbiol; 2007 Aug; 56(Pt 8):1047-1051. PubMed ID: 17644711
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Combinatory activity of linezolid and levofloxacin with antituberculosis drugs in Mycobacterium tuberculosis.
    Santos NCS; Scodro RBL; de Almeida AL; Baldin VP; Nakamura de Vasconcelos SS; Siqueira VLD; Caleffi-Ferracioli KR; Campanerut-Sá PAZ; Cardoso RF
    Tuberculosis (Edinb); 2018 Jul; 111():41-44. PubMed ID: 30029913
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Fast identification of rifampicin-and isoniazid resistance of M. Tuberculosis strains by the "TB-biochip" test system].
    Isakova ZhT
    Georgian Med News; 2008 May; (158):15-9. PubMed ID: 18560033
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Activity of the efflux pump inhibitor SILA 421 against drug-resistant tuberculosis.
    Simons SO; Kristiansen JE; Hajos G; van der Laan T; Molnár J; Boeree MJ; van Ingen J; Christensen JB; Viveiros M; Riedl Z; Amaral L; van Soolingen D
    Int J Antimicrob Agents; 2013 May; 41(5):488-9. PubMed ID: 23410790
    [No Abstract]   [Full Text] [Related]  

  • 10. Evaluation of Mycobacterium tuberculosis cross-resistance to isoniazid, rifampicin and levofloxacin with their respective structural analogs.
    Imperiale BR; Di Giulio ÁB; Adrián Cataldi A; Morcillo NS
    J Antibiot (Tokyo); 2014 Nov; 67(11):749-54. PubMed ID: 24894185
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Emergence and selection of isoniazid and rifampin resistance in tuberculosis granulomas.
    Pienaar E; Linderman JJ; Kirschner DE
    PLoS One; 2018; 13(5):e0196322. PubMed ID: 29746491
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Paradoxical effect of isoniazid on the activity of rifampin-pyrazinamide combination in a mouse model of tuberculosis.
    Almeida D; Nuermberger E; Tasneen R; Rosenthal I; Tyagi S; Williams K; Peloquin C; Grosset J
    Antimicrob Agents Chemother; 2009 Oct; 53(10):4178-84. PubMed ID: 19620331
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Vitamin C Potentiates the Killing of Mycobacterium tuberculosis by the First-Line Tuberculosis Drugs Isoniazid and Rifampin in Mice.
    Vilchèze C; Kim J; Jacobs WR
    Antimicrob Agents Chemother; 2018 Mar; 62(3):. PubMed ID: 29298757
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Drug resistance among Mycobacterium tuberculosis isolates in Lebanon.
    Hamze MM; Araj GF
    Int J Tuberc Lung Dis; 1997 Aug; 1(4):314-8. PubMed ID: 9432386
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Evaluation of the GenoType MTBDR assay for detection of rifampicin and isoniazid resistance in Mycobacterium tuberculosis complex isolates.
    Saglik I; Oz Y; Kiraz N
    Indian J Med Microbiol; 2014; 32(3):318-22. PubMed ID: 25008829
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Phenotypically occult multidrug-resistant Mycobacterium tuberculosis: dilemmas in diagnosis and treatment.
    Ho J; Jelfs P; Sintchencko V
    J Antimicrob Chemother; 2013 Dec; 68(12):2915-20. PubMed ID: 23838950
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Antimycobacterial susceptibility evaluation of rifampicin and isoniazid benz-hydrazone in biodegradable polymeric nanoparticles against
    Hakkimane SS; Shenoy VP; Gaonkar SL; Bairy I; Guru BR
    Int J Nanomedicine; 2018; 13():4303-4318. PubMed ID: 30087562
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Characteristics and treatment outcomes of INH-resistant or RFP-resistant tuberculosis].
    Saito W; Nagayama N; Miyamoto M; Hara H; Suzuki J; Masuda K; Baba M; Tamura A; Nagai H; Akagawa S; Kawabe Y; Machida K; Kurashima A; Yotsumoto H
    Kekkaku; 2003 Oct; 78(10):611-7. PubMed ID: 14621568
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Anti-mycobacterial activities of synthetic cationic α-helical peptides and their synergism with rifampicin.
    Khara JS; Wang Y; Ke XY; Liu S; Newton SM; Langford PR; Yang YY; Ee PL
    Biomaterials; 2014 Feb; 35(6):2032-8. PubMed ID: 24314557
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Rapid phenotypic assay of antimycobacterial susceptibility pattern by direct mycobacteria growth indicator tube and phage amplified biological assay compared to BACTEC 460 TB.
    El-Sayed Zaki M; Goda T
    Tuberculosis (Edinb); 2007 Mar; 87(2):102-8. PubMed ID: 17035089
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 32.